SINOMED(SH:688108)2025-04-25 14:53Financial Performance - The company's revenue for Q3 2024 reached ¥104,794,180.69, representing a year-on-year increase of 25.76%[2] - The net loss attributable to shareholders was ¥14,406,461.69, with a year-to-date loss of ¥10,915,893.04[2] - The company reported a year-to-date increase of 30.20% in revenue, primarily driven by a significant rise in coronary product sales[6] - The net profit attributable to shareholders for the year-to-date period increased by 73.85%, influenced by revenue growth and lower growth rates in operating costs and sales expenses[6] - Total operating revenue for the first three quarters of 2024 reached CNY 318,486,443.24, an increase of 30.2% compared to CNY 244,617,074.10 in the same period of 2023[17] - The net loss for the first three quarters of 2024 was CNY 14,931,400.83, compared to a net loss of CNY 44,634,324.37 in the same period of 2023, indicating an improvement[18] Research and Development - Research and development expenses totaled ¥59,721,899.55 for the quarter, an increase of 58.46% compared to the same period last year[2] - R&D expenses accounted for 56.99% of total revenue, up 11.76 percentage points year-on-year[2] - The company is focusing on key milestone clinical trial expenses as part of its ongoing R&D projects[7] - Research and development expenses surged to CNY 106,407,498.18, a significant increase of 32.3% from CNY 80,498,702.34 in the previous year[17] Assets and Liabilities - Total assets increased by 6.83% from the end of the previous year, reaching ¥1,266,868,249.18[3] - Total assets reached ¥1,266,868,249.18, compared to ¥1,185,821,379.98, marking a growth of approximately 6.8%[14] - The total liabilities increased to CNY 381,227,223.14 from CNY 324,171,588.85, marking a growth of 17.6%[16] - Non-current liabilities rose to CNY 224,486,551.62, up from CNY 172,899,093.28, reflecting a 29.8% increase[16] - The company's total equity increased to CNY 885,641,026.04 from CNY 861,649,791.13, showing a growth of 2.8%[16] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥49,720,487.28, reflecting a 37.18% increase[2] - Cash inflow from operating activities for the first three quarters of 2024 was $379,785,264.54, an increase of 18.4% compared to $320,671,351.90 in the same period of 2023[21] - Net cash flow from operating activities increased to $49,720,487.28, up 37.2% from $36,245,821.18 year-over-year[21] - Cash inflow from financing activities rose to $121,906,687.94, compared to $63,000,000.00 in the previous year, marking a significant increase of 93.5%[22] - The ending cash and cash equivalents balance increased to $224,939,661.92, compared to $189,369,325.44 at the end of the same period last year, reflecting a growth of 18.8%[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,402[9] - The largest shareholder, Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd., holds 71,859,417 shares, accounting for 17.38% of total shares[9] - The company has not reported any significant changes in the shareholding structure or related party transactions among the top shareholders[10] Operational Insights - There are no significant reminders or additional important information regarding the company's operational situation during the reporting period[12] - The company plans to continue its market expansion and product development strategies to enhance future performance[20] - The cash flow statement for the first three quarters of 2024 indicates ongoing financial challenges, with net cash flow from operating activities remaining a focus area[19] Accounting Practices - The company did not apply new accounting standards for the current year, maintaining consistency in financial reporting[23]